Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Immune Design (NASDAQ:IMDZ) initiated with Outperform rating and $18 (107% upside) price target by Leerink.
The webcast for the second quarter financial results will start at 1:30 PM PT on the 9th of this month http://ir.immunedesign.com/eventdetail.cfm?EventID=174934
(A Phase I should be happening some time next year)
Immune Design and Gritstone Oncology Announce Clinical Collaboration for Neoantigen Cancer Immunotherapy
SEATTLE and SOUTH SAN FRANCISCO, Calif. and EMERYVILLE Calif,, May 09, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, and Gritstone Oncology, a private cancer immunotherapy company developing next-generation, personalized cancer therapeutics, today announced a clinical collaboration for development of novel, personalized immunotherapies combining both companies' leading technologies.
The collaboration will involve the application of Immune Design's ZVexTM discovery platform with Gritstone's proprietary genomics and proteomics platform for identification of patient-specific tumor antigens to develop neoantigen-based immunotherapies. Immune Design and Gritstone will be jointly responsible for development activities, with an initial likely focus in non-small cell lung cancer. The first clinical trial is expected to commence in 2017.
"The emerging tumor neoantigen field holds great potential for the successful application of cancer immunotherapies, and we are pleased to be working with Gritstone, a company that we believe is a pioneer in the field," said Carlos Paya, M.D., Ph.D., president and chief executive officer of Immune Design. "Having validated our two platforms in clinical trials targeting conserved tumor antigens, we believe their application to patient specific tumor antigens is a natural next step."
For the first trial of their technologies, the companies are evaluating combining the Gritstone and Immune Design neoantigen vaccine with a checkpoint inhibitor, to optimize the vaccine-induced immune response at several levels and maximize the likelihood of clinical efficacy.
"We are excited to work with Immune Design and their novel immunotherapy approach," said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone Oncology. "There is good evidence that viral vectors are one of the most effective means of generating high titer CD8+ T cells that recognize encoded antigens, and so this is a logical move for our company, as our neoantigen prediction platform starts to deliver immune targets for individual patients with lung cancer."
http://ir.immunedesign.com/releasedetail.cfm?releaseid=969865
Immune Design Releases New PFS, OS and TME Data from Trials of Three Immuno-Oncology Product Candidates
LV305, CMB305 and G100 Data at ASCO and June 8 NYC Update Event
SEATTLE and SOUTH SAN FRANCISCO, Calif., June 08, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced updated results from clinical trials of three immuno-oncology product candidates demonstrating promising and potentially clinically meaningful anti-tumor immune responses for Immune Design's lead products. This includes data presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) annual meeting and involves Immune Design's two distinct immunotherapy applications — the ‘Specific Antigen' and ‘Endogenous Antigen' Approaches.
"The data reflect single agent Phase 1 studies and provide strong rationale for continued development, including our ongoing randomized Phase 2 studies," said Carlos Paya, M.D., Ph.D., President and Chief Executive Officer. "We believe both of our approaches are disruptive and have the potential to impact the immunotherapy treatment landscape."
LV305 & CMB305: Specific Antigen Approach Targeting NY-ESO-1 Positive Tumors — Emerging Profile of Prolonged Survival Benefit
LV305 Phase 1 single agent trial completed in 24 patients with advanced or metastatic sarcoma cancers expressing NY-ESO-1 (ASCO abstract #3093)
Median overall survival (OS) has not been reached. One-year survival is 81%.
Median progression free survival (PFS) is 4.6 months.
14 patients (58%) had clinical benefit: One patient (4%) had a late-onset partial response and 13 patients (54%) had stable disease.
7/11 patients with pretreatment progressive disease (PD) had SD or PR following LV305.
Safety profile is very favorable, with only Grade 1/2 adverse effects (AEs).
CMB305 Phase 1 single agent trial ongoing in patients with NY-ESO-1 positive soft tissue sarcomas (preliminary analysis of first 14 patients)
Median OS has not been reached. 93% (13/14 patients) survival to date.
Median PFS is 5.5 months.
Best response to date is stable disease (10/14, 71%)
Safety profile is very favorable, with only Grade 1/2 AE
G100: Intratumoral Immune Activation Approach: Transforming "cold" tumors to "hot" tumors
G100 single agent and in combination with radiation in patients with Merkel cell carcinoma (ASCO Abstract #3021)
In final results from 10 patients, G100 produced a 50% overall response rate (ORR) per protocol, including a pathologic complete response (CR) following single agent G100 alone.
Four patients remain relapse-free in long-term follow up (range 13+ to 27.5+ months).
Analysis of the tumor microenvironment (TME) in G100-treated patients demonstrates the transformation of a "cold" to a "hot" tumor: increase of innate immune molecules that favor immune cell chemotaxis; increased NK cells and M1 macrophage markers; and dendritic cell antigen presentation. In addition, trafficking of CD4 and CD8 T cells from the stroma into the tumor bed was observed.
These changes in the TME were most prominent in the G100 responding patients.
No treatment-related AEs where observed; all AEs were grade 1/2.
Immune Design Company Update June 8
Immune Design will host a Company Update Event: "Progress, Platforms and Paths Forward" on Wednesday, June 8, at 5 p.m. Eastern. Presenters will include: David Baltimore, Ph.D., President Emeritus, California Institute of Technology; Nobel Laureate; Francine M. Foss, M.D., Professor of Medicine, Yale Cancer Center, and Robert G. Maki, M.D., Ph.D., Professor of Medicine, Pediatrics and Orthopaedics, Mt. Sinai Hospital; Director of Translational Research, Sarcoma Alliance for Research Through Collaboration.
A live webcast will be available online from the investor relations page of the company's corporate website at http://ir.immunedesign.com/events.cfm. After the live webcast, an archive of the presentation will be available on the company website for 30 days.
Investors and analysts who would like to attend the Immune Design event in New York should contact Jennifer Cortes at jennifer.cortes@immunedesign.com.
http://ir.immunedesign.com/releasedetail.cfm?ReleaseID=974801
The two abstracts from this year's ASCO meeting - Single-Agent LV305 Induces Anti-tumor Immune And Clinical Responses In Patients With Advanced Or Metastatic Sarcoma And Other Cancers Expressing NY-ESO-1 http://www.immunedesign.com/wp-content/uploads/2016/06/LV305-ASCO-poster-2016-final-31May2016-v01.pdf and Pilot Trial Of Intratumoral G100, A Toll-like Receptor-4 (TLR4) Agonist, In Patients With Merkel Cell Carcinoma: Final Clinical Results And Immunologic Effects On The Tumor Microenvironment http://www.immunedesign.com/wp-content/uploads/2016/06/MCC-ASCO-poster-final-31May2016-v01.pdf
Thank you.
I will email you a few tickers.
That's really nice of you.
You have a great weekend yourself my friend.
Best of luck with all your trades.
Hi Tpizzazz24,
It would be great if I could take all the credit for the hard work but in reality a computer script is just gathering the latest news. You can go visit http://www.ddnotesmaker.com/ and type in your symbol and it highlights the text, you press control-c to copy it into memory and the control-v to paste the contents into an investorshub message, then preview it and edit it before posting. It take a minute to do. The rest of the process, scanning for symbols and selecting charts that's all me and my scans I have been working on since the late 1990s and keep that technique to myself of course.
If you want me to post ddnotes for some symbols here just email me at stocktrademan@inbox.com it won't take more than a few minutes if I have spare posts left. No problem...have a good weekend also!
Thanks for the DD.
You do a hell of a job as always.
Wish I came across this 5 weeks ago.
Will try and read over the DD this weekend.
I ran across the name on Twitter by someone who is also invested in ADA*
Would love to see a copulation of DD on that and TPI*
What's your rate?
Both could have a lot of growth in 2016.
Thanks again for all your hard work!
Have a great weekend!
$IMDZ recent news/filings
bullish 20.785
## source: finance.yahoo.com
Wed, 25 Nov 2015 16:24:43 GMT ~ How Has Smart Money Been Trading Kandi Technolgies Corp. (KNDI)?
read full: http://www.insidermonkey.com/blog/how-has-smart-money-been-trading-kandi-technolgies-corp-kndi-388881/
*********************************************************
Thu, 19 Nov 2015 18:04:24 GMT ~ IMMUNE DESIGN CORP. Financials
read full: http://finance.yahoo.com/q/is?s=imdz
*********************************************************
Wed, 18 Nov 2015 15:32:03 GMT ~ Can The Uptrend Continue for Immune Design (IMDZ)?
read full: http://finance.yahoo.com/news/uptrend-continue-immune-design-imdz-153203451.html
*********************************************************
Fri, 13 Nov 2015 15:35:03 GMT ~ Immune Design Posts Narrower-Than-Expected Loss for Q3
read full: http://finance.yahoo.com/news/immune-design-posts-narrower-expected-153503875.html
*********************************************************
Thu, 12 Nov 2015 22:10:10 GMT ~ Immune Design stock drops after $7.4 million loss
read full: http://www.bizjournals.com/seattle/blog/health-care-inc/2015/11/immune-design-stock-drops-after-7-4-million-loss.html?ana=yahoo
*********************************************************
$IMDZ charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$IMDZ company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/IMDZ/company-info
Ticker: $IMDZ
OTC Market Place: Not Available
CIK code: not found
Company name: Immune Design Corp.
Incorporated In:
$IMDZ share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$IMDZ extra dd links
Company name: Immune Design Corp.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/IMDZ/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/IMDZ/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=IMDZ+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=IMDZ+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=IMDZ+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/IMDZ/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/IMDZ/news - http://finance.yahoo.com/q/h?s=IMDZ+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/IMDZ/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/IMDZ/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/IMDZ/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/IMDZ/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/IMDZ/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/IMDZ/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/IMDZ/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/IMDZ/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=IMDZ+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/IMDZ
DTCC (dtcc.com): http://search2.dtcc.com/?q=Immune+Design+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Immune+Design+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Immune+Design+Corp.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/IMDZ/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/IMDZ
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/IMDZ/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/IMDZ/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/IMDZ/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/IMDZ/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/IMDZ/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/IMDZ/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/IMDZ/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=IMDZ&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=IMDZ
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/IMDZ/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=IMDZ+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=IMDZ+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=IMDZ
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=IMDZ
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=IMDZ+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/IMDZ/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=IMDZ+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/IMDZ.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=IMDZ
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/IMDZ/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/IMDZ/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/IMDZ/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/IMDZ/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/IMDZ
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/IMDZ
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/IMDZ:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=IMDZ
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=IMDZ
$IMDZ DD Notes ~ http://www.ddnotesmaker.com/IMDZ
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
63
|
Created
|
11/25/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |